Iclaprim met the primary endpointIclaprim was well tolerated in the study Additional data from ...
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong ...
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and ...
